Advertisement
Singapore markets closed
  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     
  • Nikkei

    39,583.08
    +241.54 (+0.61%)
     
  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     
  • FTSE 100

    8,225.40
    +45.72 (+0.56%)
     
  • Bitcoin USD

    61,379.91
    +260.99 (+0.43%)
     
  • CMC Crypto 200

    1,280.86
    -2.97 (-0.23%)
     
  • S&P 500

    5,482.87
    +4.97 (+0.09%)
     
  • Dow

    39,164.06
    +36.26 (+0.09%)
     
  • Nasdaq

    17,858.68
    +53.53 (+0.30%)
     
  • Gold

    2,340.10
    +3.50 (+0.15%)
     
  • Crude Oil

    82.41
    +0.67 (+0.82%)
     
  • 10-Yr Bond

    4.2880
    -0.0280 (-0.65%)
     
  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     
  • Jakarta Composite Index

    7,063.58
    +95.63 (+1.37%)
     
  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

Strong results from Eli Lilly’s obesity medicine in a sleep apnea trial could upset the sleep apnea industry, while greatly expanding insurance coverage for the Lilly drug. Shares of ResMed which sells CPAP machines that treat sleep apnea, were falling sharply Monday. ResMed’s stock was down 11% to $183.34 near midday, putting it on track for its largest decline since Aug. 4, when it dropped 19%, according to Dow Jones Market Data.